Anthony El-Khoueiry, MD
Medical Oncology · Los Angeles, CANPI 1891730412
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $109,816 of the $155,985 with a category attached, or 70.4%. It is spread thinly across 22 manufacturers, the largest accounting for just 17.4%.
Across 141 payments — averaging $1106.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$27K
- F. Hoffmann-la Roche AG$22K
- Merck$21K
- AstraZeneca$16K
- Exelixis Inc.$15K
- Eisai Inc.$9K
- plus $46K from 16 others
Across 1,030 payments — averaging $10,037 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.8M
- AstraZeneca$1.6M
- Merck$1.3M
- Bayer$1M
- GSK$721K
- Amgen$513K
- plus $3.4M from 26 others
What the payments were for
- Consulting fees$109,81670%
- Speaking & faculty fees$16,58911%
- Travel & lodging$24,72516%
- Food & beverage$4,8473%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 13 | $27,129 |
| F. Hoffmann-la Roche AG | 6 | $21,614 |
| Merck | 19 | $20,661 |
| AstraZeneca | 21 | $16,405 |
| Exelixis Inc. | 21 | $15,051 |
| Eisai Inc. | 10 | $9,446 |
| Genentech USA, Inc. | 13 | $9,111 |
| Daiichi Sankyo Company LTD | 4 | $8,124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $7,100 |
| Jazz Pharmaceuticals Inc. | 1 | $3,348 |
| Bayer | 5 | $3,339 |
| Terumo Medical Corporation | 3 | $3,025 |
| Janssen Scientific Affairs, LLC | 3 | $2,855 |
| Servier Pharmaceuticals LLC | 2 | $2,811 |
| AbbVie | 1 | $2,100 |
| Pfizer | 5 | $1,938 |
| Astrazeneca UK Limited | 1 | $1,713 |
| Tesaro, Inc. | 2 | $76 |
| Amgen | 2 | $39 |
| Boston Scientific | 1 | $38 |
| Johnson & Johnson(2 entities) | 2 | $35 |
| Incyte Corporation | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,985 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron HclOndansetron Hcl/Pf | 14 | $134 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.